An analysis of monocytes and dendritic cells differentiated from human peripheral blood monocyte-derived induced pluripotent stem cells.
Noriko HiramatsuNaoki YamamotoSumito IsogaiTakanori OnouchiMasaya HirayamaShingo MaedaTakuma InaMasashi KondoKazuyoshi ImaizumiPublished in: Medical molecular morphology (2019)
Dendritic cell-based immunotherapy, which uses a patient's own immune cells, can be used for cancer treatment and allergy control, such as autoimmune disease and rejection associated with transplantation. However, these treatments create a burden on patients due to repeated blood collection. We used cell biological analysis of monocytes with few mutations obtained from minimal blood collection for genome recombination. Next, we established human peripheral blood monocyte-derived induced pluripotent stem cells (iPSCs) using a commercial vector and standard culture method. We found that when established iPSCs were induced to differentiate, monocytes showed phagocytic properties and expressed CD14 and CX3CR1. Further, the generated dendritic cells (DCs) expressed CCL17 and highly expressed HLA-DR following the addition of the mite antigen. Taken together, these data show that monocyte-derived iPS cells can be used to differentiate into monocytes and DCs. In addition, the use of these cells can be applied to the pathological analysis of dendritic cell therapy and monocyte diseases.
Keyphrases
- induced pluripotent stem cells
- dendritic cells
- peripheral blood
- cell therapy
- induced apoptosis
- regulatory t cells
- immune response
- end stage renal disease
- cell cycle arrest
- stem cells
- chronic kidney disease
- newly diagnosed
- ejection fraction
- mesenchymal stem cells
- endothelial cells
- multiple sclerosis
- cell death
- case report
- peritoneal dialysis
- prognostic factors
- high glucose
- single cell
- drug induced
- signaling pathway
- dna repair
- liver fibrosis
- diabetic rats
- data analysis
- atopic dermatitis
- allergic rhinitis